Pureogen, a subsidiary of Amicogen (CEO Park Cheol), a specialized company in biopharmaceuticals and bio materials, announced on the 17th that it has won the Korea Excellent Patent Award for its biopharmaceutical purification resin (hereinafter referred to as resin).
The product that received the Excellent Patent Award is Amicogen’s subsidiary Pureogen’s ‘Puriose®’ resin. Amicogen secured ligand technology, which determines resin performance, based on protein engineering technology, and introduced carrier technology from Swedish BioWorks to develop resin technology through Pureogen.
The Excellent Patent Award comprehensively evaluates the technology’s ▲expertise ▲competitiveness ▲productivity, meaning this award signifies that Pureogen’s resin has secured competitiveness not only in the domestic market but also overseas.
Pureogen (CEO Byun Jang-woong) was established in 2021 as the first chromatography resin manufacturer in Korea. It develops various resins for biopharmaceutical purification and sells products such as Protein A resin and ion exchange resins under the Puriose® brand.
Puriose® incorporates resin manufacturing technology that enhances durability and highly develops porosity. It also significantly reduces production costs to secure price competitiveness and can be used without performance changes during the process due to minimal pressure impact at high flow rates.
Byun Jang-woong, CEO of Pureogen, said, “Through continuous research, we plan to develop next-generation resins with improved performance and provide excellent resins tailored to customer needs by optimizing manufacturing processes. Resin is an essential material for purifying proteins and antibodies during biopharmaceutical development and production stages. Along with media for cell culture, it is considered a core component material in biopharmaceuticals.”
He added, “Our company holds a portfolio of all types of resins, including affinity (ProA, ProG, ProL), ion exchange (S, Q, DEAE, CM), hydrophobic, and size exclusion. Recently, we secured a large-scale resin factory with a capacity of 10,000L in Yeosu. This patent award confirms there is no doubt about the global competitiveness of our resin. We will do our best to become the nation’s first specialized resin company in name and reality.”
Meanwhile, Amicogen is evolving into a global pharmaceutical and bio material company through enzymes, ligands, new materials, resins, and media, which are core materials used in the pharmaceutical bio industry based on platform technologies such as gene evolution, high-throughput screening (HTS), and protein engineering. Recently, it secured a 106-ton media factory in Songdo, Incheon, and a 10,000L (with plans to expand up to 50,000L) resin factory in Yeosu, establishing itself as a leading domestic pharmaceutical and bio material company.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
